article · Pediatric Health Medicine and Therapeutics
Uganda has launched a nationwide mandatory newborn screening programme for sickle cell disease, where an estimated 20,000 affected infants are born annually. While the policy relies on rapid diagnostic tests linked to central laboratories, current operations face delays of four to six weeks and miss private births and older children. A differentiated framework proposes tailoring screening tools to specific health contacts and age groups. Private facilities would deploy microchip electrophoresis analysers at birth to counter fetal haemoglobin interference. Public facilities would integrate rapid tests such as Sickle SCAN or HemoTypeSC into routine immunisation visits from six weeks onward, prioritising the nine-month visit as fetal haemoglobin falls. Community catch-up would screen children aged one to five in schools. Linking all screening to a national network of one hundred laboratory hubs could reduce diagnostic confirmation turnaround times to forty-eight to seventy-two hours.
Sickle cell disease affects thousands of newborns in Uganda every year, but operational bottlenecks can delay diagnosis and life-saving care. Structuring screening around child immunisation contacts and school entry, whilst using appropriate diagnostics at each stage, provides a practical roadmap to deliver universal screening. Decentralising confirmation testing significantly reduces waiting times for families.
The framework directly informs health system implementers and diagnostic manufacturers about deployment pathways for point-of-care tools like Gazelle, Sickle SCAN, and HemoTypeSC. These applied, commercially available diagnostics are positioned for integration into routine public immunisation programmes, private clinics, and a national network of regional laboratory hubs. This clarifies viable market entry points across public and private healthcare sectors in sub-Saharan Africa.
AI-generated from the published abstract. Always read the original work before citing.
Uganda's sickle cell disease (SCD) prevalence of 1.3% and sickle cell trait (SCT) prevalence of 13.3% nationally represent a substantial public health burden, with an estimated 20,000 affected infants born annually. On 9 February 2026, Uganda's Ministry of Health launched a nationwide mandatory newborn screening programme for SCD, placing the country among the first in sub-Saharan Africa to implement universal birth screening. This policy builds on over a decade of evidence, including the Uganda Sickle Surveillance Study, and cost-effectiveness analyses showing dried blood spot (DBS) screening costs of $5.88 per child, with viable point-of-care thresholds of $3.07-$5.09. However, the initial rollout relies on rapid diagnostic tests within existing hub-and-CPHL systems and does not yet fully cover private facility births, immunization-based catch-up for missed cases, or older unscreened children. In addition, the current 4-6-week turnaround time with centralized confirmation at Central Public Health Laboratories remains an operational limitation. We propose a differentiated implementation framework to strengthen the programme. It aligns screening strategies with care entry points and age-specific test performance. Private facilities would use a microchip electrophoresis analyzer (Gazelle™) at birth due to reduced accuracy of lateral flow tests in high fetal hemoglobin. Public facilities would integrate Sickle SCAN or HemoTypeSC into immunization contacts from six weeks of age, with the 9-month contact prioritized as the most reliable screening timepoint given the progressive decline in HbF, and school-based programmes would target children aged 1-5 years who were previously missed. All pathways would connect to Uganda's 100-laboratory hub network for electrophoretic confirmation, potentially reducing turnaround time to 48-72 hours. By leveraging existing delivery, immunization, and laboratory infrastructure, this framework offers a feasible and equitable route to translate Uganda's mandatory screening policy into large-scale health impact.
This page summarises published work. The authoritative version sits with the publisher.
DOI: 10.2147/phmt.s621156
Is something wrong with this record? Report it or request removal.
Discussion
Have you built on this work, tried to replicate it, or seen it applied in practice? Share what you know. Verified researchers and MARATTO™ domain experts can open a discussion, and any member can reply. Contributions are reviewed before they appear.
No discussion yet. Open the first thread.
New to MARATTO™? Create a free account.
